The possible role of myelin destruction as a precipitating event in Alzheimer's disease.
Noble
Mark
M
Department of Biomedical Genetics, University of Rochester Medical Center, Rochester, NY 14642, USA. mark_noble@urmc.rochester.edu
D015761:4-Aminopyridine / Q000627:therapeutic use; D000544:Alzheimer Disease / Q000209:etiology / Q000378:metabolism* / Q000628:therapy; D000818:Animals; D000906:Antibodies / Q000627:therapeutic use; D002490:Central Nervous System / Q000378:metabolism / Q000473:pathology; D003711:Demyelinating Diseases / Q000150:complications* / Q000188:drug therapy; D051100:Glial Cell Line-Derived Neurotrophic Factor; D006801:Humans; D009186:Myelin Sheath / Q000378:metabolism* / Q000473:pathology; D009414:Nerve Growth Factors / Q000627:therapeutic use; D009836:Oligodendroglia / Q000187:drug effects / Q000378:metabolism*; D026902:Potassium Channel Blockers / Q000627:therapeutic use
D000906:Antibodies; C495039:GDNF protein, human; D051100:Glial Cell Line-Derived Neurotrophic Factor; D009414:Nerve Growth Factors; D026902:Potassium Channel Blockers; D015761:4-Aminopyridine